GENPREX INC. DL-,0001
GENPREX INC. DL-,0001
Share · US3724462037 · GNPX · A3E3Z3 (XNCM)
Overview
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
0
0
0
No Price
27.10.2025 21:48
Current Prices from GENPREX INC. DL-,0001
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
GNPX
USD
27.10.2025 21:48
8,62 USD
-0,99 USD
-10,30 %
Share Float & Liquidity
Free Float 99,74 %
Shares Float 667.696,00
Shares Outstanding 669.405,00
Company Profile for GENPREX INC. DL-,0001 Share
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Get up to date insights from finAgent about GENPREX INC. DL-,0001

Company Data

Name GENPREX INC. DL-,0001
Company Genprex, Inc.
Symbol GNPX
Website https://www.genprex.com
Primary Exchange XNCM Frankfurt
WKN A3E3Z3
ISIN US3724462037
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Ryan M. Confer
Country United States of America
Currency EUR
Employees 0,0 T
Address 3300 Bee Cave Road, 78746 Austin
IPO Date 2018-03-29

Stock Splits

Date Split
21.10.2025 1:50

Ticker Symbols

Name Symbol
Frankfurt 2DE0.F
NASDAQ GNPX
More Shares
Investors who hold GENPREX INC. DL-,0001 also have the following shares in their portfolio:
Bangun Kosambi Sukses Tbk.
Bangun Kosambi Sukses Tbk. Share
WORLD BK 23/30
WORLD BK 23/30 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025